---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000110"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:19:19.682905+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Praxis reports Q3 net loss $73.9M; ulixacaltamide Phase 3 positive; pro forma cash ~$956M

## Summary
- Ulixacaltamide met primary endpoints in both Essential3 Phase 3 studies for essential tremor; pre-NDA meeting with FDA scheduled Q4 2025.
- Q3 net loss $73.9M vs $51.9M YoY; R&D expenses rose to $65.8M from $41.9M.
- Cash and marketable securities $389.2M at Sept 30; October public offering added ~$567M net, extending runway into 2028.
- Vormatrigine POWER1 study for focal onset seizures fully enrolled; topline expected 1H 2026.
- Relutrigine interim analysis for SCN2A/SCN8A DEEs planned Q4 2025; if positive, NDA submission possible early 2026.

## SEC filing metadata
- accession: 0001689548-25-000110
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/0001689548-25-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/prax-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000110
- JSON: https://secwatch.observer/filing/0001689548-25-000110.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.